News

Insights on the Future Direction of Stora Enso's Leadership

Insights on the Future Direction of Stora Enso's Leadership

Proposals for Stora Enso Oyj's Board of Directors

STORA ENSO OYJ STOCK EXCHANGE RELEASE - The Shareholders' Nomination Board has shared recommendations ahead of Stora Enso Oyj's upcoming Annual General Meeting. These proposals, made public well in advance, prepare the ground for a comprehensive evaluation of the company's leadership.

The Board will ask for approval of its composition, suggesting that eight members will continue to serve on the Board of Directors. Among the current members, notable leaders such as Håkan Buskhe, Helena Hedblom, Astrid Hermann, Christiane Kuehne, Richard Nilsson, Elena Scaltritti, and Antti Vasara are nominated for re-election. Additionally, Jouko Karvinen is proposed to join the Board as a new member, marking a significant transition within the leadership structure.

Leadership Changes and Acknowledgments

As part of their announcements, both Kari Jordan, the Chair, and Reima Rytsölä stated that they will not seek re-election. Marcus Wallenberg, Chair of the Shareholders' Nomination Board, offered gratitude for their dedicated service, especially highlighting Kari Jordan's critical role over the past four years in driving Stora Enso's strategic focus and encouraging valuable transformations in the company.

"I thank Kari for his exceptional service. His leadership helped pivot our operational focus and enhance our financial performance," Wallenberg remarked, emphasizing the balance achieved during his tenure.

New Appointments: Fostering Continuity and Strategy

The nomination suggests that Håkan Buskhe will step into the role of Chair, while Jouko Karvinen is proposed for the Vice Chair position. This leadership pairing is viewed as instrumental in maintaining the company’s strategic direction.

Jouko Karvinen, a seasoned executive and former CEO of Stora Enso, brings a wealth of industrial expertise back to the Board. His previous roles across major corporations like Philips and ABB reflect a robust background in leadership and corporate governance.

Focus on Competence and Governance

The Shareholders' Nomination Board emphasizes a governance model aligned with Nordic standards, ensuring nominees possess the requisite skills while also maintaining overall Board competency. This careful selection process underscores the Board’s commitment to fulfilling the broader goals outlined in the Finnish Corporate Governance Code applicable to listed entities.

Remuneration for Board Members

In addition to the proposed changes in leadership, the Nomination Board outlined the remuneration structure for Board positions, recommending that the annual payments remain consistent with the previous year's levels. For 2025, the remuneration is set as follows:

Board of Directors

Chair: EUR 221,728
Vice Chair: EUR 125,186
Members: EUR 85,933

The board remuneration will comprise 40% payable in Stora Enso's shares and the balance in cash. This performance-based structure not only aligns the interests of Board members with the company’s performance but also promotes long-term commitment.

Committee Remuneration Adjustments

The Nomination Board also reviewed committee remuneration, deciding to maintain the annual compensation levels for specific committees, including the Financial and Audit Committee, the People and Culture Committee, and the Sustainability and Ethics Committee. The remuneration for committee chairs and members, respectively, is recommended as follows:

Financial and Audit Committee
Chair: EUR 23,976
Members: EUR 16,868

People and Culture Committee
Chair: EUR 11,988
Members: EUR 7,214

Sustainability and Ethics Committee
Chair: EUR 11,988
Members: EUR 7,214

During the period leading up to the AGM, the Shareholders' Nomination Board held six meetings to finalize their proposals, and every member actively participated in these discussions, advocating for transparency and inclusiveness in the review process.

Stora Enso's Vision and Market Position

Stora Enso's commitment to sustainability is reflected in its operations centered around renewable resources. The company stands as a leader in packaging, biomaterials, and wooden construction, while being one of the largest private forest holders globally. With approximately 19,000 employees, Stora Enso reported sales of EUR 9 billion, showcasing a robust market presence. Stora Enso shares are recognized on Nasdaq Helsinki Oy and Nasdaq Stockholm AB, ensuring accessibility for a wide range of investors.

As Stora Enso continues to transition towards a sustainable future, they aim to reshape the concept of renewable materials, advocating that everything currently produced with fossil-based resources can be constructed using trees tomorrow. This vision not only encases a forward-thinking approach but also aligns with global sustainability initiatives.

Frequently Asked Questions

What changes are proposed for the Board of Directors at Stora Enso?

The Shareholders' Nomination Board has proposed to continue with eight members and re-elect several current members while adding Jouko Karvinen as a new member.

Who will be the new Chair and Vice Chair of the Board?

Håkan Buskhe is proposed to become the Chair, with Jouko Karvinen nominated for the Vice Chair position.

What is the remuneration structure for Board members?

The remuneration will remain the same as in 2025, with a substantial portion to be paid in shares, promoting alignment with company performance.

How many meetings did the Shareholders' Nomination Board hold?

The Shareholders' Nomination Board convened six times to discuss the proposals for the AGM and ensure thorough deliberation.

What is Stora Enso’s focus as a company?

Stora Enso aims to lead in renewable products, emphasizing a sustainable approach to materials, advocating that all fossil-based products can be produced from trees in the future.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 157

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 70

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 192

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 147

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading

Top 5 Most Recently Viewed Articles

Container Store Group Faces Delisting by NYSE Amid Market Challenges

Updated Category News Views 145

Container Store Group's NYSE Delisting Announcement The New York Stock Exchange (NYSE) has made a significant announcement regarding the trading status of The Container Store Group, Inc. (TCS). The Exchange's staff has determined that it will initiate proceedings to delist the Company's common stock. This decision comes in light of the Company's recent performance in the...

Continue Reading
Investing in Vanguard Russell 2000 ETF: A Strategic Approach

Updated Category News Views 200

Investing in the Vanguard Russell 2000 ETF: A Strategic Approach In recent years, the stock market's performance has been largely driven by large corporations. While megacap tech stocks have thrived, small-cap stocks have struggled to keep pace. This has resulted in significant valuation discounts for smaller companies compared to their larger peers. Over the past five...

Continue Reading
Welcoming Ann Dunkin to Our Esteemed Board of Directors

Updated Category News Views 156

Ann Dunkin Joins Our Board of Directors We are thrilled to announce the appointment of Ann Dunkin, P.E., to our Board of Directors. With an extensive background in engineering and a strong commitment to public service, Ann's diverse expertise will be invaluable as we navigate the challenges and opportunities in our industry. Professional Background of Ann Dunkin Ann...

Continue Reading
Management Trading Insights on Unexpected Developments

Updated Category News Views 150

Understanding Management Trading Activities When assessing a company's health and future prospects, observing management trading can provide invaluable insights. Executive transactions—buying or selling shares—often reflect their confidence in the business's performance. An increase in stock purchases by management usually signals optimism, while significant sales may...

Continue Reading
Tovecimig's Efficacy in Biliary Tract Cancer Study Unveiled

Updated Category News Views 254

Breakthrough Findings in Biliary Tract Cancer Treatment Compass Therapeutics, Inc. has announced promising interim results from their ongoing Phase 2/3 study, COMPANION-002, examining the efficacy of tovecimig, formerly known as CTX-009, in combination with paclitaxel for treating advanced biliary tract cancer (BTC). Tovecimig, a bispecific antibody targeting both DLL4...

Continue Reading